uniQure (NASDAQ:QURE) Shares Up 8.7% – Time to Buy?

uniQure N.V. (NASDAQ:QURE) shares were up 8.7% during mid-day trading on Tuesday . The stock traded as high as $51.38 and last traded at $51.5660. 1,429,167 shares traded hands during trading, a decline of 41% from the average session volume of 2,414,303 shares. The stock had previously closed at $47.46.

Analyst Ratings Changes

A number of research firms have recently issued reports on QURE. Royal Bank Of Canada upped their target price on shares of uniQure from $35.00 to $65.00 and gave the stock an “outperform” rating in a report on Thursday, June 18th. Stifel Nicolaus set a $28.00 price target on shares of uniQure in a research note on Tuesday, May 5th. Mizuho boosted their price target on shares of uniQure from $35.00 to $68.00 and gave the stock an “outperform” rating in a research report on Thursday, June 25th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of uniQure in a research note on Friday, June 26th. Finally, The Goldman Sachs Group increased their price objective on shares of uniQure from $14.00 to $46.00 and gave the company a “neutral” rating in a report on Thursday, June 18th. Thirteen research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $65.00.

uniQure Stock Down 1.1%

The company has a debt-to-equity ratio of 0.15, a current ratio of 10.01 and a quick ratio of 10.01. The business’s 50 day simple moving average is $44.32 and its 200 day simple moving average is $29.24. The company has a market capitalization of $3.49 billion, a PE ratio of -12.64 and a beta of 0.92.

uniQure (NASDAQ:QURE) last posted its earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.40). The firm had revenue of $5.84 million during the quarter, compared to analyst estimates of $5.45 million. uniQure had a negative net margin of 1,350.73% and a negative return on equity of 111.96%. During the same quarter in the previous year, the firm earned ($0.69) earnings per share. As a group, analysts anticipate that uniQure N.V. will post -3.74 earnings per share for the current fiscal year.

Insider Buying and Selling

In other uniQure news, CEO Matthew C. Kapusta sold 164,429 shares of the firm’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $44.32, for a total transaction of $7,287,493.28. Following the completion of the sale, the chief executive officer owned 558,810 shares of the company’s stock, valued at $24,766,459.20. This trade represents a 22.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Walid Abi-Saab sold 30,000 shares of uniQure stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $46.42, for a total value of $1,392,600.00. Following the completion of the sale, the insider owned 148,235 shares in the company, valued at $6,881,068.70. This represents a 16.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 388,229 shares of company stock valued at $16,817,099 in the last ninety days. Company insiders own 4.65% of the company’s stock.

Institutional Trading of uniQure

Institutional investors and hedge funds have recently bought and sold shares of the stock. Avoro Capital Advisors LLC increased its position in shares of uniQure by 38.4% during the fourth quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock valued at $147,170,000 after acquiring an additional 1,705,556 shares during the last quarter. State Street Corp lifted its holdings in shares of uniQure by 123.8% in the 4th quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock worth $77,319,000 after acquiring an additional 1,787,033 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of uniQure by 155.3% in the 4th quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock worth $70,226,000 after acquiring an additional 1,785,275 shares during the last quarter. California State Teachers Retirement System boosted its position in shares of uniQure by 6,641.2% during the 2nd quarter. California State Teachers Retirement System now owns 2,423,263 shares of the biotechnology company’s stock worth $111,615,000 after purchasing an additional 2,387,316 shares during the period. Finally, Orbimed Advisors LLC boosted its position in shares of uniQure by 189.7% during the 1st quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock worth $34,926,000 after purchasing an additional 1,398,749 shares during the period. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.